Top

Published in:

01-08-2013 | REVIEW ARTICLE

Ghrelin Could be a Candidate for the Prevention of In-Stent Restenosis

Authors: Z. W. Shu, M. Yu, X. J. Chen, X. R. Tan

Published in: Cardiovascular Drugs and Therapy | Issue 4/2013

Abstract

Percutaneous coronary intervention is a revolutionary treatment for ischemic heart disease, but in-stent restenosis (ISR) remains a clinical challenge. Inflammation, smooth muscle proliferation, endothelial function impairment, and local thrombosis have been identified as the main mechanisms for ISR. Considering the multifactorial mechanisms of ISR, a novel therapeutic agent with multiple bioactivities is required. Ghrelin is a novel gut–brain peptide predominantly produced by the stomach, and has been shown to play a role in various cardiovascular activities, such as increasing myocardial contractility, improving cardiac output, and inhibiting ventricular remodeling, as well as attenuating cardiac ischemia-reperfusion injury. Recent studies have demonstrated that ghrelin effectively inhibits vascular inflammation and vascular smooth muscle cell proliferation, repairs endothelial cells, promotes vascular endothelial function, inhibits platelet aggregation, and exerts antithrombotic effects. These findings suggest that ghrelin may be an innovative therapeutic candidate for the prevention and treatment of ISR.

Kim MS, Dean LS. In-stent restenosis. Cardiovasc Ther. 2011;29:190–8.PubMedCrossRef

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.PubMedCrossRef

Garcia EA, Korbonits M. Ghrelin and cardiovascular health. Curr Opin Pharmacol. 2006;6:142–7.PubMedCrossRef

Granata R, Baragli A, Settanni F, Scarlatti F, Ghigo E. Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J Mol Endocrinol. 2010;45:107–18.PubMedCrossRef

Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell. 2008;132:387–96.PubMedCrossRef

Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004;110:3674–9.PubMedCrossRef

Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, Yoshida M, et al. Ghrelin supresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol. 2008;294:H426–32.PubMedCrossRef

Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, et al. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol. 2004;43:165–70.PubMedCrossRef

Drachman DE, Simon DI. Inflammation as a mechanism and therapeutic target for in-stent restenosis. Curr Atheroscler Rep. 2005;7:44–9.PubMedCrossRef

10.

Waseem T, Duxbury M, Ito H, Ashley SW, Robinson MK. Exogenous Ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery. 2008;143:334–42.PubMedCrossRef

11.

Sharma V, McNeill JH. The emerging roles of leptin and Ghrelin in cardiovascular physiolosy and pathophysioloy. Curr Vasc Pharmacol. 2005;3:169–80.PubMedCrossRef

12.

Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, et al. Ghrelin inhibits pro-inflammatory responses and nuclear factor kappaB activation in human endothelial cells. Circulation. 2004;109:2221–6.PubMedCrossRef

13.

Deng B, Xie XM, Chen XB. Relationship of ghrelin level to inflammatory factor and endothelial relaxation function in metabolic syndrome patients. Chin J Arterioscler. 2010;18:487–91.

14.

Granado M, Priego T, Martin AI, Villanúa MA, López-Calderón A. Anti-inflammatory effect of the Ghrelin agonist growth hormone releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288:E486–92.PubMedCrossRef

15.

Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, et al. Ghrelin inhibits leptin-and activation-induced pro-inflammatory cytokine expression by human monocytes and T cells. J Clin Investig. 2004;114:57–66.PubMed

16.

Zhao D, Zhan Y, Zeng H, Moyer MP, Mantzoros CS, Pothoulakis C. Ghrelin stimulates interleukin-8 gene expression through protein kinase C-mediated NF-κB pathway in human colonic epitheial cells. J Cell Biochem. 2006;97:1317–27.PubMedCrossRef

17.

Xia Q, Pang W, Pan H, Zheng Y, Kang JS, Zhu SG. Effects of Ghrelin on the proliferation and secretion of splenic T lymphocytes in mice. Regul Pept. 2004;122:173–8.PubMedCrossRef

18.

Chow KB, Cheng CH, Wise H. Anti-inflammatory activity of ghrelin in human carotid artery cells. Inflammation. 2009;32:402–9.PubMedCrossRef

19.

Skilton MR, Nakhla S, Sieveking DP, Caterson ID, Celermajer DS. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. Clin Exp Pharmacol Physiol. 2005;32:839–44.PubMedCrossRef

20.

Huang CX, Yuan MJ, Huang H, Wu G, Liu Y, Yu SB, et al. Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect. Peptides. 2009;30:2286–91.PubMedCrossRef

21.

Marks AR. Rapamycin: signaling in vscular smooth muscle. Transplant Proc. 2003;35:231S–3S.PubMedCrossRef

22.

Willis AI, Pierre-Paul D, Stunpio BE, Gahtan V. Vascular smooth muscle cell migration:current research and clinical implications. Vasc Endovasc Surg. 2004;38:11–23.CrossRef

23.

Chen J, Han Y, Lin C, Zhen Y, Song X, Teng S, et al. PDGF-D contributes to neointimal hyperplasia in rat model of vessel injury. Biochem Biophys Res Commun. 2005;29:976–83.CrossRef

24.

Lavezzi AM, Ottaviani G, Matturri L. Biology of the smooth muscle cells in human atherosclerosis. APMIS. 2005;113:112–21.PubMedCrossRef

25.

Deng DX, Spin JM, Tsalenko A, Vailaya A, Ben-Dor A, Yakhini Z, et al. Molecular signatures determining coronary artery and saphenous vein smooth muscle cell phenotypes: distinct responses to stimuli. Arterioscler Thromb Vasc Biol. 2006;26:1058–65.PubMedCrossRef

26.

Zhan M, Yuan F, Liu H, Chen H, Qiu X, Fang W. Inhibition of proliferation and apoptosis of vascular smooth muscle cells by ghrelin. Acta Biochim Biophys Sin (Shanghai). 2008;40:769–76.

27.

Rossi F, Castelli A, Bianco MJ, Bertone C, Brama M, Santiemma V. Ghrelin inhibits contraction and proliferation of human aortic smooth muscle cells by cAMP/PKA pathway activation. Atherosclerosis. 2009;203:97–104.PubMedCrossRef

28.

Li GZ, Jiang W, Zhao J, Pan CS, Cao J, Tang CS, et al. Ghrelin blunted vascular calcification in vivo and in vitro in rats. Regul Pept. 2005;129:167–76.PubMedCrossRef

29.

Liang QH, Jiang Y, Zhu X, Cui RR, Liu GY, Liu Y, et al. Ghrelin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the ERK pathway. PLoS One. 2012;7:e33126.PubMedCrossRef

30.

Hu CZ, Cao YL, Huo HY, Zhao WH, Hu J. Inhibitory effect of ghrelin on nicotine-induced VCAM-1expression in human umbilical vein endothelial cells. J Cardiovasc Pharmacol. 2009;53:241–5.PubMedCrossRef

31.

Xu YP, Zhu JJ, Cheng F, Jiang KW, Gu WZ, Shen Z, et al. Ghrelin ameliorates hypoxia-induced pulmonary hypertension via phospho-GSK3β/β-catenin signaling in neonatal rats. J Mol Endocrinol. 2011;47:33–43.PubMedCrossRef

32.

Shimizu Y, Nagaya N, Teranishi Y, Imazu M, Yamamoto H, Shokawa T, et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun. 2003;310:830–5.PubMedCrossRef

33.

Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation. 2005;112:2986–92.PubMed

34.

Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI3-kinase/AKT. J Cell Biol. 2002;159:1029–37.PubMedCrossRef

35.

Zhan H, Liu G, Wang Q, Ding L, Cai H, Jiang H, et al. Effect of Ghrelin on human endothelial cells apoptosis induced by high glucose. Biochem Biophys Res Commun. 2007;362:677–81.CrossRef

36.

Deng B, Fang L, Chen X, Chen M, Xie X. Effect of ghrelin on angiotensin II induced human umbilicus vein endothelial cell oxidative stress and endothelial cell injury. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35:1037–47.PubMed

37.

Xiang Y, Li Q, Li M, Wang W, Cui C, Zhang J. Ghrelin inhibits AGEs-induced apoptosis in human endothelial cells involving ERK1/2 and PI3K/Akt pathways. Cell Biochem Funct. 2011;29:149–55.PubMedCrossRef

38.

Rossi F, Castelli A, Bianco MJ, Bertone C, Brama M, Santiemma V. Ghrelin induces proliferation in human aortic endothelial cells via ERK1/2 and PI3K/Akt activation. Peptides. 2008;29:2046–51.PubMedCrossRef

39.

Hedayati N, Annambhotla S, Jiang J, Wang X, Chai H, Lin PH, et al. Growth hormone-releasing peptite ghrelin inhibits homocysteine-induced endothelial dysfunction in porcine coronary arteries and human endothelial cells. J Vasc Surg. 2009;49:199–207.PubMedCrossRef

40.

Rossi F, Bertone C, Petricca S, Santiemma V. Ghrelin inhibits angiotensin-II induced migration of human aortic endothelial cells. Atherosclerosis. 2007;192:291–7.PubMedCrossRef

41.

Conconi MT, Nico B, Guidolin D, Baiguera S, Spinazzi R, Rebuffat P, et al. Ghrelin inhibits FGF-2-mediated angiogenesis in vitro and in vivo. Peptides. 2004;25:2179–85.PubMedCrossRef

42.

Ahluwalia A, Li A, Cheng G, Deng X, Tarnawski AS. Reduced ghrelin in endothelial cells plays important mechanistic role in aging-related impairment of angiogenesis. J Physiol Pharmacol. 2009;60:29–34.PubMed

43.

Ferns GA, Avades TY. The mechanisms of coronary restenosis:insight from experimental models. Int J Exp Pathol. 2000;81:63–88.PubMedCrossRef

44.

Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol. 2007;558:7–13.PubMedCrossRef

45.

Kantorova E, Chomova M, Kurca E, Sivak S, Zelenak K, Kučera P, et al. Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke. Neuroendocrinol Lett. 2011;32:716–21.PubMed

46.

Arici OF, Cetin N. Protective role of ghrelin against carbon tetrachloride (CCl₄)-induced coagulation disturbances in rats. Regul Pept. 2011;166:139–42.PubMedCrossRef

Title: Ghrelin Could be a Candidate for the Prevention of In-Stent Restenosis
Authors: Z. W. Shu
M. Yu
X. J. Chen
X. R. Tan
Publication date: 01-08-2013
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue 4/2013
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-013-6453-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ghrelin Could be a Candidate for the Prevention of In-Stent Restenosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Nitroglycerin does not Interfere with Protection by Remote Ischemic Preconditioning in Patients with Surgical Coronary Revascularization under Isoflurane Anesthesia

Cardioprotection by Farnesol: Role of the Mevalonate Pathway

Outcomes, Health Costs and Use of Antiplatelet Agents in 7,082 Patients Admitted for an Acute Coronary Syndrome Occurring in a Large Community Setting

The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular Protection: Current Position and Perspectives

Beneficial Effects of Intracoronary Nicorandil on Microvascular Dysfunction After Primary Percutaneous Coronary Intervention: Demonstration of Its Superiority to Nitroglycerin in a Cross-Over Study

What is the Role of Erythropoietin in Acute Myocardial Infarct? Bridging the Gap Between Experimental Models and Clinical Trials